Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: A multicenter, retrospective study in Korea (KROG 11-04)

Jin Hee Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Sung Whan Ha, Kyubo Kim, Yongbae Kim, Ji Woon Yea, Min Kyu Kang, Kyung Hwan Shin, Dong Won Kim, Ji Hae Lee, Chang-Ok Suh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To estimate the effect of boost radiotherapy on local recurrence-free survival (LRFS) in patients with ductal carcinoma in situ (DCIS) breast cancer. We included patients from nine institutions who met the following criteria: having Tis, age 18 years or older, having breast conserving surgery (BCS) and radiotherapy within 12 weeks after surgery. From 1995 through 2006, 728 patients were analyzed retrospectively by the Korean Radiation Oncology Group. All patients received whole-breast radiation therapy (WBRT) after BCS. 232 patients (31.9 %) also received boost radiation therapy (RT) (median 10 Gy). After median follow-up of 82 months, 5-year LRFS was 98.4 % and 10-year LRFS was 95.8 % for all patients. There was no statistically significant difference of LRFS between the boost and no-boost groups. Nineteen (2.6 %) patients had ipsilateral breast recurrences, including 12 of invasive recurrence and 7 DCIS. The presence of the HER2 receptor was associated with more invasive recurrences. Nine (1.2 %) patients developed contralateral breast cancer, including six invasive breast cancer and three DCIS. In the multivariate analysis, only the margin status was a significant prognostic factor for LRFS. Boost RT was not associated with further improvement of local control in DCIS after BCS and WBRT. HER2 receptor-positive patients may need further treatment with the anti-HER2 agents.

Original languageEnglish
Pages (from-to)341-345
Number of pages5
JournalBreast Cancer Research and Treatment
Volume146
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Korea
Multicenter Studies
Radiotherapy
Retrospective Studies
Breast Neoplasms
Recurrence
Segmental Mastectomy
Survival
Breast
Radiation Oncology
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Jin Hee ; Choi, Doo Ho ; Park, Won ; Ahn, Seung Do ; Kim, Su Ssan ; Ha, Sung Whan ; Kim, Kyubo ; Kim, Yongbae ; Yea, Ji Woon ; Kang, Min Kyu ; Shin, Kyung Hwan ; Kim, Dong Won ; Lee, Ji Hae ; Suh, Chang-Ok. / Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer : A multicenter, retrospective study in Korea (KROG 11-04). In: Breast Cancer Research and Treatment. 2014 ; Vol. 146, No. 2. pp. 341-345.
@article{f8c5bacc5100416cb31320dacbcdc0ad,
title = "Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: A multicenter, retrospective study in Korea (KROG 11-04)",
abstract = "To estimate the effect of boost radiotherapy on local recurrence-free survival (LRFS) in patients with ductal carcinoma in situ (DCIS) breast cancer. We included patients from nine institutions who met the following criteria: having Tis, age 18 years or older, having breast conserving surgery (BCS) and radiotherapy within 12 weeks after surgery. From 1995 through 2006, 728 patients were analyzed retrospectively by the Korean Radiation Oncology Group. All patients received whole-breast radiation therapy (WBRT) after BCS. 232 patients (31.9 {\%}) also received boost radiation therapy (RT) (median 10 Gy). After median follow-up of 82 months, 5-year LRFS was 98.4 {\%} and 10-year LRFS was 95.8 {\%} for all patients. There was no statistically significant difference of LRFS between the boost and no-boost groups. Nineteen (2.6 {\%}) patients had ipsilateral breast recurrences, including 12 of invasive recurrence and 7 DCIS. The presence of the HER2 receptor was associated with more invasive recurrences. Nine (1.2 {\%}) patients developed contralateral breast cancer, including six invasive breast cancer and three DCIS. In the multivariate analysis, only the margin status was a significant prognostic factor for LRFS. Boost RT was not associated with further improvement of local control in DCIS after BCS and WBRT. HER2 receptor-positive patients may need further treatment with the anti-HER2 agents.",
author = "Kim, {Jin Hee} and Choi, {Doo Ho} and Won Park and Ahn, {Seung Do} and Kim, {Su Ssan} and Ha, {Sung Whan} and Kyubo Kim and Yongbae Kim and Yea, {Ji Woon} and Kang, {Min Kyu} and Shin, {Kyung Hwan} and Kim, {Dong Won} and Lee, {Ji Hae} and Chang-Ok Suh",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10549-014-3025-4",
language = "English",
volume = "146",
pages = "341--345",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer : A multicenter, retrospective study in Korea (KROG 11-04). / Kim, Jin Hee; Choi, Doo Ho; Park, Won; Ahn, Seung Do; Kim, Su Ssan; Ha, Sung Whan; Kim, Kyubo; Kim, Yongbae; Yea, Ji Woon; Kang, Min Kyu; Shin, Kyung Hwan; Kim, Dong Won; Lee, Ji Hae; Suh, Chang-Ok.

In: Breast Cancer Research and Treatment, Vol. 146, No. 2, 01.01.2014, p. 341-345.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer

T2 - A multicenter, retrospective study in Korea (KROG 11-04)

AU - Kim, Jin Hee

AU - Choi, Doo Ho

AU - Park, Won

AU - Ahn, Seung Do

AU - Kim, Su Ssan

AU - Ha, Sung Whan

AU - Kim, Kyubo

AU - Kim, Yongbae

AU - Yea, Ji Woon

AU - Kang, Min Kyu

AU - Shin, Kyung Hwan

AU - Kim, Dong Won

AU - Lee, Ji Hae

AU - Suh, Chang-Ok

PY - 2014/1/1

Y1 - 2014/1/1

N2 - To estimate the effect of boost radiotherapy on local recurrence-free survival (LRFS) in patients with ductal carcinoma in situ (DCIS) breast cancer. We included patients from nine institutions who met the following criteria: having Tis, age 18 years or older, having breast conserving surgery (BCS) and radiotherapy within 12 weeks after surgery. From 1995 through 2006, 728 patients were analyzed retrospectively by the Korean Radiation Oncology Group. All patients received whole-breast radiation therapy (WBRT) after BCS. 232 patients (31.9 %) also received boost radiation therapy (RT) (median 10 Gy). After median follow-up of 82 months, 5-year LRFS was 98.4 % and 10-year LRFS was 95.8 % for all patients. There was no statistically significant difference of LRFS between the boost and no-boost groups. Nineteen (2.6 %) patients had ipsilateral breast recurrences, including 12 of invasive recurrence and 7 DCIS. The presence of the HER2 receptor was associated with more invasive recurrences. Nine (1.2 %) patients developed contralateral breast cancer, including six invasive breast cancer and three DCIS. In the multivariate analysis, only the margin status was a significant prognostic factor for LRFS. Boost RT was not associated with further improvement of local control in DCIS after BCS and WBRT. HER2 receptor-positive patients may need further treatment with the anti-HER2 agents.

AB - To estimate the effect of boost radiotherapy on local recurrence-free survival (LRFS) in patients with ductal carcinoma in situ (DCIS) breast cancer. We included patients from nine institutions who met the following criteria: having Tis, age 18 years or older, having breast conserving surgery (BCS) and radiotherapy within 12 weeks after surgery. From 1995 through 2006, 728 patients were analyzed retrospectively by the Korean Radiation Oncology Group. All patients received whole-breast radiation therapy (WBRT) after BCS. 232 patients (31.9 %) also received boost radiation therapy (RT) (median 10 Gy). After median follow-up of 82 months, 5-year LRFS was 98.4 % and 10-year LRFS was 95.8 % for all patients. There was no statistically significant difference of LRFS between the boost and no-boost groups. Nineteen (2.6 %) patients had ipsilateral breast recurrences, including 12 of invasive recurrence and 7 DCIS. The presence of the HER2 receptor was associated with more invasive recurrences. Nine (1.2 %) patients developed contralateral breast cancer, including six invasive breast cancer and three DCIS. In the multivariate analysis, only the margin status was a significant prognostic factor for LRFS. Boost RT was not associated with further improvement of local control in DCIS after BCS and WBRT. HER2 receptor-positive patients may need further treatment with the anti-HER2 agents.

UR - http://www.scopus.com/inward/record.url?scp=84904110897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904110897&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3025-4

DO - 10.1007/s10549-014-3025-4

M3 - Article

C2 - 24939061

AN - SCOPUS:84904110897

VL - 146

SP - 341

EP - 345

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -